1 g., infertility, menstrual disturbances, and impotence).

2 ding fatigue, chronic inflammation, and male impotence.

3 environment for discussion and management of impotence.

4 e the first-line therapy in the treatment of impotence.

5 r wetness (7% v 32%) and had a lower rate of impotence (23% v 56% for men < 70 years), while they wer

6 h the exception of an increased incidence of impotence among men who received megestrol acetate.

7    With increasing availability of drugs for impotence and advanced reproductive technologies for the

8 entation, balance disturbances, vertigo, and impotence), and 3 ("arthro-myo-neuropathy," characterize

9 llular carcinoma, diabetes, cardiac failure, impotence, and arthritis.

10 ealth, diabetes, arthropathies, arrhythmias, impotence, and skin pigmentation were no more prevalent

11  who are more bothered by their urination or impotence are more likely to report worse quality of lif

12 ore surgery, the proportion of men reporting impotence at 18 or more months after surgery varied acco

13 us ends of spindle microtubules, whereas its impotence at minus ends permits continued microtubule de

14 -5 (PDE5) inhibitor, is widely used to treat impotence by improving penile blood flow via elevation o

15 ies provide novel insight into the phagocyte impotence caused by ACT, which not only impairs neutroph

16  with them, while other side effects such as impotence, decreased libido, fatigue, and hot flashes pr

17 including graft contracture, recurrence, and impotence have been reported.

18              With the exception of increased impotence in MA-treated patients, toxicity was comparabl

19    In addition, competition study showed the impotence of SPD to replace with histone H1 in histone H

20 lity, insomnia, weakness, diminished libido, impotence, poor memory, reduced muscle and bone mass, an